Nanjing Vazyme Biotech Co., Ltd., a biotechnology company, engages in the research, development, and production of enzymes, antigens, antibodies, and polymer organic materials. The company offers scientific research reagents, such as PCR clone point mutation, nucleic acid extraction, reverse transcription, qPCR, cell/protein, gene editing series, and instant granules; high-throughput sequencing library construction reagents, including DNA and RNA library, single cell epigenetic, magnetic, quantitative series, and cell-free DNA storage and extractions; and biomedical reagents and services. It serves scientific research institutions, high-throughput sequencing service companies, molecular diagnostic reagent manufacturers, pharmaceutical companies, CRO companies, hospitals, and other medical institutions. The company was founded in 2012 and is based in Nanjing, China.

Nanjing Vazyme Biotech Co., Ltd.

诺唯赞 is a biotechnology company that engages in the research and development of enzymes, antigens, antibodies, and other functional proteins along with high molecular organic materials. The company provides solutions in life sciences, in vitro diagnostics, and biomedicine.

诺唯赞

Vazyme Biotech | 23,381 followers on LinkedIn. A Global Supplier Dedicated to Design, Manufacture and Application of Bioactive Proteins. | Vazyme (688105.SH) is a global technology and service provider that dedicated to the design, manufacture, and application of bioactive proteins and continuously expands the application fields of core technologies in life science, in vitro diagnostics, bio-medicine, and others. To meet the varying needs of our customers and partners, we have developed over 600 types of genetically engineered recombinant enzymes and over 2,500 types of high-performance materials and over 2,000 end products. While remaining steadfast to high quality standards, producing all core materials in-house and adhering to GMP quality control standards, we endeavor to maintain a stable and sufficient supply for global customers by establishing subsidiary companies and local warehouses.

International Business Development, Country Manager (Seoul, South Korea) Drug Discovery, Assay Development and NGS Library Preparation Reagents

Birendra Kumar Singh

CEO at Qingtang Investment Group expertized in the biomedical industry

Hua Xu

Preventing and controlling viral diseases

Dr. Arslan Mehboob_PhD

Director of Europe Marketing Department

Cécile L.

Vazyme Biotech

We may grow up, but we never let go of the little one within us. Life is more beautiful with a touch of childlike wonder! 🎉 Happy #WorldChildrensDay 🎉 Whether you’re looking for the perfect big one or a cute mini one, we’ve got you covered! 🧪🧫 https://bit.ly/3ALpf4E #HappyChildrensDay #science #lab

See our footprint in Thailand! 🌏 🚀 At Vazyme, we believe in the power of connection! Our recent Master qPCR session with Dr. Hang Zhao was a hit, with attendees in Thailand tuning in to learn and share their insights. The presentation covered essential aspects of mastering qPCR, helping address overlooked details and common challenges, all aimed at empowering participants in their scientific journeys. The energy in the room was inspiring, proving that our passion for science knows no bounds! 💬🔍 #biotech #qPCR #Innovation

🎥 #MEDICA 2024 has been a fantastic experience! Check out our highlight video showcasing our time at Booth HALL 3/B46. We had such meaningful conversations and connections with all of you! We look forward to seeing you next year! Until then, stay connected! 🌐 #Healthcare #medical #Biotech #Microfluidics #alzheimersdisease

💬 Day 2 at #MEDICA 2024 is all about connection! Vazyme is thrilled to engage with our customers at Booth HALL 3/B46. Your feedback inspires us, and we’re eager to hear your thoughts! Let’s collaborate for a brighter future in microfluidics. If you’re at the event, drop by for a chat! #Healthcare #medical #Biotech #Microfluidics #alzheimersdisease

🎉 We’re live from #MEDICA 2024 in Germany! Come check out our advanced Logicore System with leading digital microfluidic technology at Booth HALL 3/B46! Come by, say hello, and let’s explore the future of diagnostics together. We can’t wait to meet you! 🐼✨ #Healthcare #medical #Biotech #Microfluidics #alzheimersdisease

🧪 Your Expertise Needed! We want to know: which detection method do you trust for Mycoplasma contamination? Join our poll and share your thoughts! Every vote counts! 🌟 #LifeScience #Biotech #Mycoplasma #quiz

🌐 What a memorable event at the #ASHG Annual Meeting in Denver! Thank you for the engaging discussions! We're always here to assist you in your research and advance the biotech industry together! #lifescience #Biotech #lab #Genetics #Genomics #HumanGenetics #Research

💡Imagine if we could make testing for infectious diseases more convenient and accurate—what would that mean for us? 🌟Vazyme Logicore System is designed for accuracy and efficiency, delivering results in approximately one hour. Don’t miss out on the future of health testing! 🗓️Join us at MEDICA from Nov 11-14 to see it live >> https://bit.ly/3UrfZZZ 🎥 Don’t forget to watch our video! #LifeSciences #Biotech #MEDICA2024 #Microfluidics

🔬 Looking for a reliable solution for RNA extraction? Meet FreeZol Reagent, designed for efficient total RNA extraction with unmatched purity! No chloroform needed, and you can complete your extraction in just 1 hour. 🔗 Check out now>> https://bit.ly/40B3jDY #LifeScience #Biotech #RNAextraction #DNAextraction

🌟 Yes! We are here at #MEDICA ! Visit us at booth HALL 3/B46 to explore our advanced Logicore System with leading digital microfluidic technology in action. Don't miss the opportunity to connect with our team and discover reliable solutions. See you there! 👋✨

	Mar '20	Jun '20	Sep '20	Dec '20	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
revenue	207.27M -				541.64M -											417.55M -	299.50M 28.27%	343.61M 14.73%	336.64M 2.03%
cost of revenue	11.84M -				40.93M -												87.26M -	126.71M 45.22%	101.08M 20.23%
gross profit	195.43M -				500.71M -											417.55M -	212.25M 49.17%	216.90M 2.19%	235.56M 8.60%
selling and marketing expenses				60.76M -															251.83M -
general and administrative expenses								-30.91M -											137.94M -
selling general and administrative expenses																	158.54M -	162.41M 2.44%	389.77M 139.99%
research and development expenses																91.78M -	70.76M 22.90%	61.12M 13.62%	72.02M 17.83%
other expenses	-60.17M -	-139.37M 131.64%	14.77K 100.01%	-3.16M 21,502.00%	-109.16M 3,352.64%	-159.41M 46.03%	-2.71M 98.30%	-4.50M 66.16%	497.93K 111.06%	65.55M 13,064.49%	-63.92M 197.52%	195.74M 406.21%	-13.16M 106.72%	1.04M 107.88%	-10.83M 1,144.65%	-328.34M 2,932.40%	-8.70M 97.35%	-3.09M 64.49%	-217.81M 6,947.58%
cost and expenses	11.84M -				40.93M -											420.11M -	325.26M 22.58%	353.34M 8.63%	345.07M 2.34%
operating expenses	-60.17M -	-139.37M 131.64%	107.71M 177.28%	132.78M 23.27%	-109.16M 182.22%	-159.41M 46.03%	210.03M 231.75%	253.78M 20.83%	210.65M 17.00%	262.19M 24.47%	325.77M 24.25%	422.89M 29.81%	241.22M 42.96%	261.90M 8.57%	210.18M 19.75%	420.11M 99.88%	238.01M 43.35%	226.62M 4.78%	243.99M 7.66%
interest expense																	8.96M -	6.62M 26.16%	7.00M 5.79%
ebitda	195.43M -				500.71M -											12.09M -	-25.42M 310.25%	43.56M 271.39%
operating income	135.26M -				391.55M -											-2.57M -	-25.76M 903.09%	-9.72M 62.25%
depreciation and amortization	60.17M -				109.16M -											14.66M -		53.29M -	7.16M 86.57%
total other income expenses net	-63.02M -				-109.45M -											-5.07M -	23.39M 561.35%	11.86M 49.31%	155.13K 98.69%
income before tax	132.41M -				391.27M -											-7.64M -	-2.36M 69.04%	2.13M 190.28%
income tax expense	-41.69M -				-54.41M -											-14.66M -	-7.24M 50.61%	-8.29M 14.57%
net income	113.93M -	339.05M 197.60%	152.10M 55.14%	216.64M 42.43%	336.51M 55.33%	55.34M 83.55%	158.36M 186.14%	128.07M 19.13%	431.36M 236.81%	182.58M 57.67%	135.79M 25.63%	-155.99M 214.87%	-51.21M 67.17%	-30.47M 40.50%	4.70M 115.44%	7.02M 49.20%	5.22M 25.68%	10.94M 109.78%	2.00M 81.75%
weighted average shs out	400.01M -	400.01M 0%	400.01M 0%	400.01M 0%	361.84M 9.54%	400.01M 10.55%	400.01M 0%	372.03M 6.99%	399.41M 7.36%	399.41M 0%	399.41M 0%	398.82M 0.15%	389.41M 2.36%	389.41M 0%	395.23M 1.49%	392.76M 0.62%	397.00M 1.08%	395.92M 0.27%
weighted average shs out dil	400.01M -	400.01M 0%	400.01M 0%	400.01M 0%	361.84M 9.54%	400.01M 10.55%	400.01M 0%	372.03M 6.99%	399.41M 7.36%	399.41M 0%	399.41M 0%	398.82M 0.15%	389.41M 2.36%	389.41M 0%	395.21M 1.49%	392.76M 0.62%	397.00M 1.08%	395.92M 0.27%
eps	0.28 -	0.85 203.57%	0.38 55.29%	0.54 42.11%	0.93 72.22%	0.14 84.95%	0.40 185.71%	0 100%	1.08 Infinity%	0.46 57.41%	0.34 26.09%	-0.39 214.71%	-0.13 66.67%	-0.08 39.85%	0.01 115.22%	0.02 50.42%	0.01 26.82%	0.03 110.69%	0 100%
epsdiluted	0.28 -	0.85 203.57%	0.38 55.29%	0.54 42.11%	0.93 72.22%	0.14 84.95%	0.40 185.71%	0 100%	1.08 Infinity%	0.46 57.41%	0.34 26.09%	-0.39 214.71%	-0.13 66.67%	-0.08 39.85%	0.01 115.22%	0.02 50.42%	0.01 26.82%	0.03 110.69%	0 100%

6881

COM:VAZYME

诺唯赞

Last Close

23.50

25/11 07:00

Market Cap

8.03B

Beta: -

Volume Today

2.19M

Avg: -

Preview